Clinical exploration of first-line therapy in metastatic lung adenocarcinoma patients with negative or low PD-L1 expression: a retrospective cohort study
{{output}}
Background: Either Programmed cell death protein 1 (PD-1)/Programmed cell death-Ligand protein 1 (PD-L1) inhibitors plus chemotherapy or anti-angiogenic agents plus chemotherapy has become first-line therapy in negative or low PD... ...
